Production and characterization of haploidentical CD19 CAR T cells: Validated to induce a continuous complete remission in a patient with relapsed refractory B-cell ALL.
Somsak PrasongtanakijUsanarat AnurathapanThitinee VanichapolBunyada JittorntrumKorakot AtjanasuppatPongpak PongpitchaSamart PakakasamaDuantida SongdejNongnuch SirachainanKaran PaisooksantivatanaSuparerk BorwaornpinyoBorje S AnderssonSuradej HongengPublished in: Asia-Pacific journal of clinical oncology (2020)
Our CD19 CAR T cells demonstrated efficacies in acute lymphoblastic B-cell leukemia, and will be used to establish an immunotherapeutic program for high-risk B-cell acute lymphoblastic leukemia in Thailand. We propose that this approach can be used as a model for how this new exciting technology can be applied directly at individual institutions that treat (a large number of) patients with high-risk leukemia.
Keyphrases
- acute lymphoblastic leukemia
- induced apoptosis
- acute myeloid leukemia
- bone marrow
- cell cycle arrest
- liver failure
- signaling pathway
- endoplasmic reticulum stress
- oxidative stress
- respiratory failure
- stem cell transplantation
- rheumatoid arthritis
- cell proliferation
- multiple myeloma
- disease activity
- nk cells
- peripheral blood
- extracorporeal membrane oxygenation
- hepatitis b virus
- hodgkin lymphoma
- low dose
- ulcerative colitis